Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.52 USD | +1.27% | -2.84% | +44.14% |
Jun. 04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
Jun. 03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
Financials (USD)
Sales 2024 * | 553M | Sales 2025 * | 592M | Capitalization | 2.32B |
---|---|---|---|---|---|
Net income 2024 * | -175M | Net income 2025 * | -188M | EV / Sales 2024 * | 4.03 x |
Net cash position 2024 * | 90.5M | Net Debt 2025 * | 59M | EV / Sales 2025 * | 4.01 x |
P/E ratio 2024 * |
-13.4
x | P/E ratio 2025 * |
-12.6
x | Employees | 1,453 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.74% |
Latest transcript on NovoCure Limited
1 day | +1.27% | ||
1 week | -2.84% | ||
Current month | -2.23% | ||
1 month | +19.69% | ||
3 months | +45.21% | ||
6 months | +62.78% | ||
Current year | +44.14% |
Managers | Title | Age | Since |
---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01-12-31 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 14-05-31 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 03-12-31 |
Kin Yip Leung
BRD | Director/Board Member | 63 | 11-08-04 |
David Hung
BRD | Director/Board Member | 67 | 18-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 0 M€ | 0.00% | - | |
0.71% | 0 M€ | 0.00% | - | |
0.19% | 21 M€ | +8.79% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-13 | 21.52 | +1.27% | 1,098,841 |
24-06-12 | 21.25 | -0.75% | 945,440 |
24-06-11 | 21.41 | -0.23% | 948,895 |
24-06-10 | 21.46 | -0.19% | 699,525 |
24-06-07 | 21.5 | -2.93% | 1,193,416 |
Delayed Quote Nasdaq, June 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.14% | 2.32B | |
+75.69% | 12.57B | |
-25.26% | 7.29B | |
+14.20% | 7.11B | |
+15.12% | 5.5B | |
-16.74% | 4.83B | |
+16.16% | 4.14B | |
-23.67% | 3.78B | |
-29.30% | 2.67B | |
+2.72% | 2.09B |
- Stock Market
- Equities
- NVCR Stock